The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)

María Caldas; Ángeles Pérez-Aisa; Bojan Tepes; Alma Keco-Huerga; Luis Bujanda; Alfredo J. Lucendo; Luis Rodrigo; Dino Vaira; Luis Fernández-Salazar; Jose M. Huguet; Jorge Pérez-Lasala; Natasa Brglez Jurecic; Galina Fadeenko; Jesús Barrio; Miguel Areia; Juan Ortuño; Rinaldo Pellicano; Marcis Leja; Javier Molina-Infante; Pavel Bogomolov; Sergey Alekseenko; Manuel Domínguez-Cajal; Judith Gómez-Camarero; Vassiliki Ntouli; Samuel J. Martínez-Domínguez; Rafael Ruiz-Zorrilla; Oscar Núñez; Aiman Silkanovna Sarsenbaeva; Pedro Almela; Perminder Phull; Marta Espada; Ignasi Puig; Olga P. Nyssen; Francis Mégraud; Colm O’Morain; Javier P. Gisbert; Hp-EuReg Investigators

doi:10.3390/antibiotics10080965

The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)

María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, Alma Keco-Huerga, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Dino Vaira, Luis Fernández-Salazar, Jose M. Huguet, Jorge Pérez-Lasala, Natasa Brglez Jurecic, Galina Fadeenko, Jesús Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Marcis Leja, Javier Molina-Infante, Pavel BogomolovSergey Alekseenko, Manuel Domínguez-Cajal, Judith Gómez-Camarero, Vassiliki Ntouli, Samuel J. Martínez-Domínguez, Rafael Ruiz-Zorrilla, Oscar Núñez, Aiman Silkanovna Sarsenbaeva, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert^*, Hp-EuReg Investigators

^*Corresponding author for this work

Applied Medicine

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

3 Downloads (Pure)

Abstract

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

Original language	English
Article number	965
Number of pages	22
Journal	Antibiotics
Volume	10
Issue number	8
Early online date	11 Aug 2021
DOIs	https://doi.org/10.3390/antibiotics10080965
Publication status	Published - 11 Aug 2021

Bibliographical note

Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG), and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).

Data Availability Statement

The data presented in this study are available on request from the corresponding author.
Supplementary Materials are available online at https://www.mdpi.com/article/10.3390/antibiotics10080965/s1.

Keywords

Helicobacter pylori
Statins
Treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/antibiotics10080965Licence: CC BY

Caldas_et_al_role_of_statins_Antibiotics_vor
Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/4.0/).
Final published version, 1.64 MBLicence: CC BY

Cite this

Caldas, M., Pérez-Aisa, Á., Tepes, B., Keco-Huerga, A., Bujanda, L., Lucendo, A. J., Rodrigo, L., Vaira, D., Fernández-Salazar, L., Huguet, J. M., Pérez-Lasala, J., Jurecic, N. B., Fadeenko, G., Barrio, J., Areia, M., Ortuño, J., Pellicano, R., Leja, M., Molina-Infante, J., ... Hp-EuReg Investigators (2021). The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg). Antibiotics, 10(8), Article 965. https://doi.org/10.3390/antibiotics10080965

Caldas, M, Pérez-Aisa, Á, Tepes, B, Keco-Huerga, A, Bujanda, L, Lucendo, AJ, Rodrigo, L, Vaira, D, Fernández-Salazar, L, Huguet, JM, Pérez-Lasala, J, Jurecic, NB, Fadeenko, G, Barrio, J, Areia, M, Ortuño, J, Pellicano, R, Leja, M, Molina-Infante, J, Bogomolov, P, Alekseenko, S, Domínguez-Cajal, M, Gómez-Camarero, J, Ntouli, V, Martínez-Domínguez, SJ, Ruiz-Zorrilla, R, Núñez, O, Silkanovna Sarsenbaeva, A, Almela, P, Phull, P, Espada, M, Puig, I, Nyssen, OP, Mégraud, F, O’Morain, C, Gisbert, JP & Hp-EuReg Investigators 2021, 'The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)', Antibiotics, vol. 10, no. 8, 965. https://doi.org/10.3390/antibiotics10080965

@article{a997bee0cbcc460585bb08a1886ed126,

title = "The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)",

abstract = "Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.",

keywords = "Helicobacter pylori, Statins, Treatment",

author = "Mar{\'i}a Caldas and {\'A}ngeles P{\'e}rez-Aisa and Bojan Tepes and Alma Keco-Huerga and Luis Bujanda and Lucendo, {Alfredo J.} and Luis Rodrigo and Dino Vaira and Luis Fern{\'a}ndez-Salazar and Huguet, {Jose M.} and Jorge P{\'e}rez-Lasala and Jurecic, {Natasa Brglez} and Galina Fadeenko and Jes{\'u}s Barrio and Miguel Areia and Juan Ortu{\~n}o and Rinaldo Pellicano and Marcis Leja and Javier Molina-Infante and Pavel Bogomolov and Sergey Alekseenko and Manuel Dom{\'i}nguez-Cajal and Judith G{\'o}mez-Camarero and Vassiliki Ntouli and Mart{\'i}nez-Dom{\'i}nguez, {Samuel J.} and Rafael Ruiz-Zorrilla and Oscar N{\'u}{\~n}ez and {Silkanovna Sarsenbaeva}, Aiman and Pedro Almela and Perminder Phull and Marta Espada and Ignasi Puig and Nyssen, {Olga P.} and Francis M{\'e}graud and Colm O{\textquoteright}Morain and Gisbert, {Javier P.} and {Hp-EuReg Investigators}",

note = "Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG), and the Centro de Investigaci{\'o}n Biom{\'e}dica en Red de Enfermedades Hep{\'a}ticas y Digestivas (CIBERehd). ",

year = "2021",

month = aug,

day = "11",

doi = "10.3390/antibiotics10080965",

language = "English",

volume = "10",

journal = "Antibiotics",

issn = "2079-6382",

publisher = "MDPI",

number = "8",

}

TY - JOUR

T1 - The role of statins on helicobacter pylori eradication

T2 - Results from the european registry on the management of h. pylori (hp-eureg)

AU - Caldas, María

AU - Pérez-Aisa, Ángeles

AU - Tepes, Bojan

AU - Keco-Huerga, Alma

AU - Bujanda, Luis

AU - Lucendo, Alfredo J.

AU - Rodrigo, Luis

AU - Vaira, Dino

AU - Fernández-Salazar, Luis

AU - Huguet, Jose M.

AU - Pérez-Lasala, Jorge

AU - Jurecic, Natasa Brglez

AU - Fadeenko, Galina

AU - Barrio, Jesús

AU - Areia, Miguel

AU - Ortuño, Juan

AU - Pellicano, Rinaldo

AU - Leja, Marcis

AU - Molina-Infante, Javier

AU - Bogomolov, Pavel

AU - Alekseenko, Sergey

AU - Domínguez-Cajal, Manuel

AU - Gómez-Camarero, Judith

AU - Ntouli, Vassiliki

AU - Martínez-Domínguez, Samuel J.

AU - Ruiz-Zorrilla, Rafael

AU - Núñez, Oscar

AU - Silkanovna Sarsenbaeva, Aiman

AU - Almela, Pedro

AU - Phull, Perminder

AU - Espada, Marta

AU - Puig, Ignasi

AU - Nyssen, Olga P.

AU - Mégraud, Francis

AU - O’Morain, Colm

AU - Gisbert, Javier P.

AU - Hp-EuReg Investigators

N1 - Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG), and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).

PY - 2021/8/11

Y1 - 2021/8/11

N2 - Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

AB - Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

KW - Helicobacter pylori

KW - Statins

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85113804528&partnerID=8YFLogxK

U2 - 10.3390/antibiotics10080965

DO - 10.3390/antibiotics10080965

M3 - Article

AN - SCOPUS:85113804528

SN - 2079-6382

VL - 10

JO - Antibiotics

JF - Antibiotics

IS - 8

M1 - 965

ER -

The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)

Abstract

Bibliographical note

Data Availability Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this